Early clinical evidence suggests CBD can modestly reduce cannabis use and ease some withdrawal symptoms, but the research is still thin. The strongest finding comes from a single randomized trial that tested pharmaceutical-grade CBD at high doses and found it outperformed placebo on measures of cannabis use. Case reports add some supporting signal, particularly around anxiety and sleep during withdrawal. But “CBD helps you quit weed” is a much stronger claim than the current science supports, and the gap between what was tested in that trial and what you can buy at a gas station is enormous.
What the Clinical Trial Actually Found
The most rigorous evidence comes from a phase 2a trial published in The Lancet Psychiatry. Researchers enrolled 82 people seeking treatment for cannabis use disorder and randomly assigned them to receive placebo or one of several CBD doses daily for four weeks. At the end, participants taking 400 mg of CBD per day showed a measurable drop in a urine marker of cannabis use compared to placebo, along with about half an extra day per week of abstinence. The 800 mg dose also reduced the urine marker, though its effect on abstinent days was slightly weaker and less statistically certain. Both doses were well tolerated, with no severe side effects reported, and 94% of participants finished the treatment course.1PubMed Central. Cannabidiol for the treatment of cannabis use disorder: Phase IIa double-blind placebo-controlled randomised adaptive Bayesian dose-finding trial
Half a day more of abstinence per week is real but modest. It is not a miracle cure. The trial was designed primarily to figure out which doses were worth testing further, not to prove CBD works as a standalone quit-smoking intervention. A larger phase 3 trial would be needed before anyone could call this settled science. Still, the fact that a non-intoxicating compound moved the needle in a controlled setting, against placebo, in people with a diagnosed use disorder, is a meaningful starting point.
Withdrawal Symptoms and Why They Matter
One of the biggest barriers to quitting cannabis is withdrawal. People who have used heavily for months or years often experience irritability, trouble sleeping, anxiety, loss of appetite, and restlessness when they stop. These symptoms typically peak in the first week and can linger for two weeks or more. Sleep disruption is a particular problem: one clinical report documented a patient whose insomnia after stopping cannabis became severe enough to trigger worsening anxiety, mood disturbance, and even suicidal thoughts, ultimately leading to a hospital admission.2PubMed Central. The Effects of Cannabinoids on Sleep
This is where CBD’s anxiolytic and sleep-related properties become interesting. In a published case report, a patient using CBD oil reported feeling less anxious and settling into a regular sleep pattern. The patient also stopped using marijuana entirely after starting CBD, and maintained that abstinence even when the dose was tapered down from 24 mg to 18 mg daily.3PubMed Central. Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report A separate case report found that a patient treated with CBD showed no significant withdrawal, anxiety, or dissociative symptoms during the treatment period.4PubMed. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report
Case reports are the weakest form of clinical evidence. One person’s experience could be a coincidence, a placebo effect, or the result of other factors changing at the same time. But across the limited data available, a pattern emerges: CBD seems to take the edge off the anxiety and insomnia that drive many people back to cannabis use. If those symptoms are the reason you relapse, dampening them even partially could make a practical difference.
The Dose Problem
The doses used in the clinical trial were 400 mg and 800 mg of pharmaceutical-grade CBD per day. That is far more than what most commercial products deliver. A typical CBD gummy contains 10 to 25 mg. A standard dropper of a CBD tincture might give you 15 to 50 mg. To match the trial’s 400 mg dose, you would need to consume a large number of gummies or a substantial portion of a tincture bottle every single day.
Cost aside, the dose gap matters for another reason. The case report that used just 18 to 24 mg per day also saw positive results, but that was a single patient, not a controlled trial. We do not know whether low doses of CBD have any meaningful effect on cannabis use at a population level, because no one has tested it rigorously at those levels. The only controlled data we have used high doses of a carefully manufactured product. Assuming that a 25 mg gummy from a convenience store will produce the same effect is a leap the evidence does not support.
This is a genuine gap in the research. Many people experimenting with CBD as a quit aid are using products in the 25 to 100 mg per day range. Whether that range does anything for cannabis withdrawal or cravings is simply unknown. Until someone runs a trial at those lower, commercially relevant doses, the honest answer is: we do not know.
Safety at Higher Doses
If you are tempted to just take more CBD to match the trial doses, the safety data should give you pause. A phase 1 trial in healthy adults taking 1,500 mg of CBD per day found that nearly half of participants developed elevated liver enzymes, and about a third met the criteria for drug-induced liver injury.5PubMed Central. Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial A systematic review pooling data from 12 trials found that CBD use was associated with roughly a sixfold increase in the odds of liver enzyme elevation compared to placebo, with high doses and concurrent use of certain other medications identified as risk factors.6PubMed. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis
CBD also inhibits certain liver enzymes involved in processing other drugs. This means it can change how your body handles medications, potentially increasing their levels in your blood to unsafe concentrations. Liver enzyme elevations have been specifically documented when CBD is taken alongside certain medications like valproate, an anti-seizure drug.7JAMA Internal Medicine. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial If you take any prescription medication, adding high-dose CBD without telling your doctor is a genuinely risky move.
At the 400 mg dose used in the Lancet Psychiatry trial, the liver risk appears lower than at 1,500 mg, and no severe adverse events were reported in that trial. But “lower risk” is not “no risk,” and a four-week trial in 82 people cannot catch rare or slow-developing problems. The safety profile of CBD at therapeutic-level doses over months of use remains poorly understood.
The THC Contamination Issue
Here is an irony that deserves more attention: many commercial CBD products contain THC. If you are trying to quit weed and you switch to a CBD product that contains undisclosed THC, you may be unknowingly continuing to dose yourself with the very compound you are trying to stop using. A study analyzing commercially available CBD products found that many items labeled as THC-free were not, and that consumers taking these unregulated products had no clear understanding of the risk of unintended THC exposure. The consequences range from failed drug tests to legal trouble to simply undermining your quit attempt.8PubMed Central. Cannabidiol (CBD) product contamination: Quantitative analysis of Δ9-tetrahydrocannabinol (Δ9-THC) concentrations found in commercially available CBD products
An analysis of over 400 hemp-based CBD products on the German market found that about 12% contained THC above the lowest level known to produce adverse effects. The researchers also flagged broader problems with labeling, purity, and regulatory compliance across the board.9PubMed Central. Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? These findings are not unique to one country. The hemp-derived CBD market in the United States is similarly unregulated, with product quality varying enormously from brand to brand.
If you do decide to try CBD while quitting, choosing a product with a third-party certificate of analysis showing THC levels below detection limits is a minimum precaution. Even then, batch-to-batch consistency is not guaranteed with unregulated products. The pharmaceutical-grade CBD used in clinical trials is a completely different product from what you find on a shelf next to energy drinks.
CBD Versus Other Cannabinoid-Based Approaches
CBD is not the only cannabinoid that has been tested for cannabis use disorder. Nabiximols, a pharmaceutical spray containing both THC and CBD in a roughly 1:1 ratio, has also been studied. One pilot trial combining nabiximols with motivational and cognitive-behavioral therapy found that participants taking the spray reduced their cannabis consumption by about 70% compared to roughly 43% in the placebo group. However, abstinence rates after the medication phase were actually slightly higher in the placebo group.10PLOS ONE. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial
A separate study found that high fixed doses of nabiximols reduced cannabis withdrawal symptoms during abstinence compared to placebo, though they did not significantly reduce craving.11PubMed Central. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings The pattern here is interesting: cannabinoid-based treatments seem better at blunting withdrawal discomfort than at eliminating the desire to use. That is a useful distinction. If your main problem is that withdrawal makes you miserable enough to relapse, these treatments might help. If your main problem is craving itself, the evidence is weaker.
CBD-only treatment has a theoretical advantage over nabiximols for someone trying to quit: it does not contain THC, so it is not reinforcing the same reward pathway that cannabis activates. On the other hand, nabiximols may be more effective specifically because the THC component partially satisfies the brain’s adapted expectation, making the transition to full abstinence less abrupt. Neither approach has been proven to work well enough to become a standard treatment. Both remain experimental.
What About Younger Users
Cannabis use disorder is common among adolescents and young adults, and the treatment options for this age group are even more limited than for adults. One published case documented a teenager with multiple substance use problems, social anxiety, and depression who was treated with CBD capsules at doses starting at 100 mg and increasing to 600 mg over eight weeks. The patient improved on measures of depression and anxiety, stopped using illegal drugs including cannabis, and showed no withdrawal symptoms. This happened after antidepressant medication had failed.12PubMed Central. Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression
Again, this is a single case. But it is worth noting because adolescents are generally harder to study in clinical trials, and the intersection of mental health symptoms and cannabis use disorder is particularly common in younger people. For a teenager whose anxiety drives their cannabis use, addressing the anxiety might be more effective than targeting the cannabis use directly. Whether CBD is the right tool for that job, compared to established therapies, remains an open question.
The Practical Situation Right Now
There are no FDA-approved medications for cannabis use disorder. None. Not CBD, not nabiximols, not anything else. The current standard of care is behavioral therapy, and while that works for some people, quit rates are modest. This is the backdrop against which the CBD research is happening. The bar is not “does CBD work as well as the gold-standard drug,” because there is no gold-standard drug. The bar is “does CBD do better than nothing,” and the early evidence tentatively suggests it might.
If you are considering trying CBD to help quit cannabis, a few realities are worth keeping in mind. The dose that showed benefit in a controlled trial is far higher than what most commercial products provide. The commercial products themselves are inconsistently labeled and may contain THC. High-dose CBD carries a real risk of liver enzyme elevation, especially if you take other medications. And the total evidence base is one small randomized trial plus a handful of case reports. That is not nothing, but it is not much.
Behavioral approaches, particularly motivational interviewing and cognitive-behavioral therapy, remain the best-supported options. If CBD interests you as a complement to those approaches rather than a replacement, that framing is more in line with where the evidence actually stands. Talking to a clinician who can monitor your liver function and check for drug interactions is the responsible way to experiment with higher-dose CBD, rather than self-dosing from unregulated products and hoping for the best.
Why the Research Has Been So Slow
Given how many people struggle with cannabis use disorder, you might wonder why we do not have more and better data on CBD as a treatment. Part of the answer is regulatory. Cannabis and its components have been classified as controlled substances in most countries, making clinical research cumbersome and expensive to set up. Researchers need special licenses, and pharmaceutical-grade CBD is costly to produce and certify for trial use. Funding agencies have historically been more interested in studying the harms of cannabis than in studying whether one of its components might be a treatment.
There is also a conceptual oddity that slows things down: using a cannabis-derived compound to treat cannabis addiction strikes some researchers and regulators as counterintuitive, even though the pharmacology makes it perfectly sensible. CBD and THC affect the brain differently. THC is the compound that produces the high and drives the reward cycle that leads to dependence. CBD does not produce a high and appears to interact with different receptor systems. Treating one with the other is no stranger than using methadone for opioid dependence, a practice that has been standard for decades.
Phase 3 trials of CBD for cannabis use disorder are being planned or are underway, and larger studies will eventually tell us whether the promising signal from the early trial holds up. Until those results arrive, anyone using CBD to quit weed is running an experiment on themselves with limited data to guide them. That is not necessarily a reason to avoid it, but it is a reason to go in with realistic expectations and appropriate caution.